The report from the CHM Division provides an overview of the newly authorised complementary and herbal medicinal products in 2024 and illustrates trends in the numbers of medicinal products authorised in each school of therapy.
An application for orphan drug status was approved for the first time in the CHM Division (active substance: dry extract of birch bark) for the treatment of the rare disease “epidermolysis bullosa”.
Important activities of the CHM Division are also reported.